Longer persistence seen with Upadacitinib versus tumor necrosis factor inhibitors in rheumatoid arthritis
MedicalXpress
|
juil. 06, 2026
Patients with rheumatoid arthritis (RA) have longer persistence with upadacitinib than tumor necrosis factor inhibitors (TNFi), according to a study published online June 23 in Rheumatology.
This article was originally published by MedicalXpress. For more details, images, and references:
Read Full Original Article ↗